Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life sciences industry post-Brexit.
We have scrutinized the Life Sciences Industrial Strategy and found it to be a very optimistic and forward-looking document. However, when we interviewed captains of industry both within the UK and neighboring countries, they are noticeably more skeptical. How do you respond to their doubts?
"One of the tremendous advantages we have in Britain is that we possess three world-leading assets: our National Health Service, a thriving life sciences sector, and a formidable academic research base."
